Bassez et al. analyzed clinical samples from breast cancer patients who received only anti-PD1 or neoadjuvant chemotherapy before anti-PD1 using single-cell transcriptomics combined with proteome profiling to understand a subset of tumors responding to ICI. This evidence concerns the gene PDCD1 and breast carcinoma.